Spinal Muscular Atrophy (SMA) is a severe, historically devastating genetic neuromuscular disease caused by homozygous mutations or deletions in the SMN1 (Survival Motor Neuron 1) gene. Insufficient levels of functional SMN protein lead to progressive degeneration of lower motor neurons in the spinal cord, resulting in severe muscular atrophy, loss of ambulation, respiratory failure, and early mortality in pediatric patients. The human genome contains a paralogous backup gene, SMN2, but an alternative splicing defect causes roughly 90% of its transcripts to lack critical exon 7, producing a truncated, unstable SMN protein that is rapidly degraded.
The development of targeted antisense oligonucleotide (ASO) therapy has fundamentally revolutionized the clinical management of SMA. According to a recent report by Wise Guys Report, the commercial and clinical expansion of the Nusinersen Market represents a major milestone in precision genetic medicine. Nusinersen, commercially known as Spinraza, is a modified 18-mer antisense oligonucleotide designed to alter SMN2 pre-mRNA splicing. Administered via intrathecal injection directly into the cerebrospinal fluid (CSF), the molecule binds selectively to an intronic splicing silencer (ISS-N1) site in intron 7 of the SMN2 transcript.
By competitively blocking splicing repressor proteins from binding to this silencer region, nusinersen promotes the inclusion of exon 7 during mRNA transcription. This splicing alteration enables the SMN2 gene to produce full-length, functional SMN protein directly within spinal motor neurons, halting motor neuron degeneration and enabling motor milestone improvements in infants and adults across SMA Types 1, 2, and 3.
Because the phosphodiester backbone and 2'-ribose positions of nusinersen are chemically modified with phosphorothioate and 2'-O-(2-methoxyethyl) (2'-MOE) chemistries, the molecule exhibits high resistance to nuclease degradation, providing an extended biological half-life in the CSF that supports maintenance dosing every four months. As global newborn screening programs expand, early intervention with targeted splicing-modulating therapeutics continues to transform patient outcomes in genetic neuromuscular disorders.
Browse for more Reports:
Fused Silica Brick For Coke Oven Market
Sputtering Targets For Thin Film Deposition Market
